April 2011 | Volume 10 | Issue 4 | Features | 434 | Copyright © April 2011
Pipeline Previews brings to you information on the newest drugs and medical products as they become available to the dermatologic
community. This department may include additional information from the manufacturers, plus reports from physicians who wish to share
their clinical experience with these new products. In addition, we will inform our readers about the latest drugs receiving Food and Drug
Administration (FDA) approval. We trust you will find this information beneficial to your practice and research.
Resveratrol-Containing Gel for Acne
A recent pilot study showed the positive therapeutic effects of
resveratrol, a natural phytoalexin produced by grapes and other
plants, on acneic skin. In this single-blind study, which enrolled
20 patients affected by acne vulgaris, Resveratrol was incorporated
in a carboxymethylcellulose-based gel and applied daily as
a solo treatment on the right side of the face for 60 days, while
the hydrogel vehicle was applied to the left side of the face as a
control. The number and type of lesions were recorded for each
patient and the Global Acne Grading System (GAGS) score before
treatment was compared with the end of study score. In addition,
using follicular biopsy, areas of acneic skin were prepared
for histopathology and the average area occupied by microcomedones
at pre- and post-treatment was compared.
At the conclusion of the study, all patients reported to be satisfied
with the treatment and no adverse effects were reported.
Clinical evaluation showed a 53.75 percent mean reduction in
the GAGS score on the resveratrol-treated sides of the face
compared with 6.10 percent on the vehicle-treated sides of the
face. Histologic analysis showed a 66.7 percent mean reduction
in the average area of microcomedones on the resveratroltreated
sides of the face, compared with a 9.7 percent reduction
on the vehicle-treated side of the face-a clinically relevant and
statistically significant decrease of lesions in areas treated with
The full report can be found in the American Journal of Clinical
Gly-Sal Acne Body Spray
Gly-Sal Acne Body Spray is a comprehensive acne clearing system
which combines Salicylic Acid 2% USP along with the exfoliation
benefits of Glycolic Acid. It is formulated to aggressively
clear skin without over-drying. The Gly-Sal Acne Body Spray is
sold in a spray container to ease treatment of acne-prone chest
and hard to reach back acne.
Gly-Sal Acne Body Spray advertises itself as unique in that it focuses
on clearing skin blemishes as well as optimizing overall
skin health. Gly-Sal Acne Body Spray combines Salicylic Acids USP 2%, which targets comedones, and Ultra Pure Glycolic Acid
in 5% and 10% strength levels, which exfoliates the treated area,
with witch hazel - a rich source of natural tannins that work with
the ultra pure glycolic acid and salicylic acid to provide an effective
and pleasant treatment virtually free of the dryness and
discomfort that may be associated with other acne medications.
Witch hazel also delivers astringents and toning benefits.
Gly-Sal Acne Body Spray also touts that its formula penetrates
through the oils in the follicles, allowing accelerated removal of
dead skin cells, dirt and debris and reduces the number of acne
blemishes (papules & pustules) and blackheads (comedones).
It also allows the skin to heal while preventing new acne breakouts
Gly-Sal Acne Body Spray further declares that its fragrance-free
and colorant-free formula fights body acne that can be caused
by sweating and frictions from athletic gear and clothing, helps
clear and prevent acne, controls oil, reduces redness, reduces
breakouts and clogged pores, reduces inflammation of the sebaceous
glands, exfoliates the surface of the skin as well as the
follicular walls, helps enhance skin clarity, increases cell turnover
of the follicle walls and balances acid activity with hydrating
FDA Approves Natroba for Head Lice
The FDA has approved Natroba (spinosad) Topical Suspension
0.9% for the treatment of head lice infestation in patients ages
four years and older based on the results of two multicenter,
randomized, active-controlled studies. These studies enrolled
a total of 552 subjects who each received a 10-minute treatment
with Natroba. The subjects were given a second treatment
one week later if live lice were seen. 86 percent of subjects
were lice-free fourteen days after the final treatment as
compared to 44 percent of the control group.
Common adverse events reported include redness or irritation
of the eyes and skin. Natroba is not approved for use in
children younger than four years, and contains benzyl alcohol
that has been associated with serious adverse reactions and
death in neonates and low-birth weight infants.